CTLA4 deficiency in CAR-T cells improved proliferation and anti-tumor efficacy in preclinical models of leukemia and myeloma, which rescued the function of T cells from patients with leukemia that previously failed CAR-T cell treatment [94]. The gene discussed is CTLA4; the disease is leukemia.